The Food and Drug Administration has granted Fast Track designation to AMX0114 for the treatment of amyotrophic lateral sclerosis (ALS).

Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study. by Vandana Singh Benzinga Editor. Follow. Zinger Key Points.

About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig’s disease or motor neuron disease, is a fatal degenerative neurologic disorder that affects more than 55,000 people in the ...

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease in the US and Charcot’s disease in Europe, is a progressive neurodegenerative disorder affecting motor neurons in the ...

Akava Therapeutics, Inc. shares recent data suggesting that AKV9 acts on a common mechanism involved in both Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS) Akava Therapeutics ...

Announcing a new publication for Acta Materia Medica journal. Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the ...

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, invariably fatal neurological disease. No present treatments can stop or reverse the disease, although Food and Drug Administration ...

What to know about amyotrophic lateral sclerosis MRI Medically reviewed by Alana Biggers, M.D., MPH — Written by Adam Rowden on November 29, 2024 Before ALS MRI ...

The Food and Drug Administration (FDA) has not approved stem cell therapy for amyotrophic lateral sclerosis (ALS). However, people could participate in clinical trials involving this ALS treatment ...

After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for bankruptcy. The New York-based company’s chapter 11 bankruptcy was ...

Ancient viral DNA in the human genome linked to multiple sclerosis and amyotrophic lateral sclerosis. ScienceDaily . Retrieved June 11, 2025 from www.sciencedaily.com / releases / 2024 / 10 ...

Eli Lilly is splicing another asset onto its neurodegenerative disease pipeline, paying QurAlis $45 million for rights to a preclinical treatment for amyotrophic lateral sclerosis (ALS) and ...